Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Biologic Therapy in Chronic Obstructive Pulmonary Disease.

Julia W Tripple¹, Jennifer L McCracken¹, William J Calhoun¹

¹Division of Allergy and Clinical Immunology, University of Texas Medical Branch, 4.116 JSA, 301 University Boulevard, Galveston, TX 77555-0568, USA.

Immunology and Allergy Clinics of North America

|April 4, 2017

Summary

Environmental toxicants cause chronic obstructive pulmonary disease (COPD). This review examines novel biologic therapies targeting both type 1 and type 2 inflammation in COPD management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analysis of treatment pathways and long-term prevalence of pruritus after burn - An observational study with real-world data.

Burns : journal of the International Society for Burn Injuries·2026

Same author

The state of the academic medical center in allergy/immunology: Work Group Report of the AAAAI A/I Division Directors Committee.

The Journal of allergy and clinical immunology·2025

Same author

Current use and interest in complementary and alternative medicine in an academic allergy clinic.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2024

Same author

Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.

The European respiratory journal·2024

Same author

Alcohol and its metabolites dysregulate cellular bioenergetics and induce oxidative and endoplasmic reticulum stress in primary human bronchial epithelial cells.

Alcohol, clinical & experimental research·2024

Same author

Reply to "Diet may be the common factor linking aspirin-exacerbated respiratory disease and atherosclerotic cardiovascular disease".

The journal of allergy and clinical immunology. In practice·2024

Area of Science:

Pulmonary Medicine
Inflammation Research
Pharmacology

Background:

Chronic obstructive pulmonary disease (COPD) is a prevalent global health issue.
Environmental toxicants are the primary cause of COPD, triggering complex inflammatory pathways.
COPD inflammation is typically neutrophilic/macrophagic (type 1) but can involve eosinophilic (type 2) inflammation, especially during exacerbations.

Purpose of the Study:

To review clinical trials of novel biologic agents for COPD management.
To explore therapeutic targets in the multifactorial inflammatory processes of COPD.
To assess the efficacy of selective biologic therapies in addressing different inflammatory profiles in COPD.

Main Methods:

Systematic review of clinical trials involving biologic therapies in COPD.

Keywords:

Biologic therapy COPD Exacerbation IL-5 TNF-alpha

Related Experiment Videos

Analysis of studies investigating agents targeting type 1 and type 2 inflammation.

Summarization of data on the use of novel therapeutic agents in COPD management.

Main Results:

Biologic agents targeting specific inflammatory pathways are under active investigation for COPD.
Evidence is emerging on the role of type 2 inflammation in COPD exacerbations.
Novel therapies show potential in managing COPD by modulating inflammatory responses.

Conclusions:

Selective biologic agents represent a promising therapeutic avenue for COPD.
Understanding the inflammatory subtypes in COPD is crucial for personalized treatment.
Further research and clinical trials are essential to establish the role of these novel agents in COPD care.